Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: Rationale and design of the German-Austrian ABSORB RegIstRy (GABI-R)
详细信息 查看全文
- 作者：Holger Nefa ; holger.nef@innere.med.uni-giessen.de" class="auth_mail" title="E-mail the corresponding author ; Jens Wiebea ; Stefan Achenbachb ; Thomas Mü ; nzelc ; Christoph Naberd ; Gert Richardte ; Julinda Mehillif ; Jochen Wö ; hrleg ; Till Neumannh ; Janine Biermannh ; Ralf Zahni ; Johannes Kastnerj ; Axel Schmermundk ; Thomas Pfannebeckerl ; Steffen Schneiderm ; Tobias Limbourgm ; Christian W. Hamma ; n
- 关键词：ARC ; Academic Research Consortium ; BRS ; bioresorbable scaffold ; CABG ; coronary artery bypass graft surgery ; DES ; metallic drug-eluting stent ; GABI-R ; German&ndash ; Austrian ABSORB Registry ; MACE ; major adverse cardiac event ; PCI ; percutaneous coronary intervention ; PLLA ; poly-L-lactic acid ; PDLLA ; poly-D ; L-lactic acid ; QoL ; quality of life ; TLF ; target lesion failure ; TVF ; target vessel failure ; TVR ; clinically driven percutaneous or surgical target vessel revascularization
- 刊名：Cardiovascular Revascularization Medicine
- 出版年：2016
- 出版时间：January-February 2016
- 年：2016
- 卷：17
- 期：1
- 页码：34-37
- 全文大小：232 K
文摘
- •
The GABI-R addresses a lack of data about bioresorbable scaffolds in daily practice.
- •
5000 patients with minimal in- and exclusion criteria at 100 sites will be enrolled.
- •
A follow-up period of 5 years is planned.
- •
Endpoints are cardiac death, myocardial infarction, target vessel and target lesion revascularization.
- •
Symptoms, quality of life and economical aspects will be evaluated as well.